NCT02969564 18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients. Status COMPLETED Phase N/A
NCT02964988 uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Status TERMINATED Phase PHASE2
NCT02880943 Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) Status UNKNOWN Phase PHASE1/PHASE2
NCT02826382 Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 Status COMPLETED Phase EARLY_PHASE1
NCT02810262 Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) Status UNKNOWN Phase N/A
NCT02715856 Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases Status TERMINATED Phase NA
NCT02616016 MRI Guided HIFU for Palliation of Painful Skeletal Metastases in Children Status WITHDRAWN Phase NA
NCT02582749 Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases Status TERMINATED Phase PHASE2
NCT02410044 Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer Status COMPLETED Phase N/A
NCT02376322 Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients With KPS Status COMPLETED Phase PHASE2
NCT02364115 Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study Status COMPLETED Phase NA
NCT02356497 Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort Status RECRUITING Phase N/A
NCT02226276 Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer Status ACTIVE_NOT_RECRUITING Phase NA
NCT02163226 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Status COMPLETED Phase PHASE2/PHASE3
NCT02051218 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT01992016 A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine Status COMPLETED Phase NA